David C Kaslow

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
  2. doi Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus
    Peggy A Lalor
    Vical, Inc, San Diego, California 92121, USA
    J Infect Dis 197:1643-52. 2008
  3. pmc Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization
    George Jiang
    Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910 7500, USA
    Malar J 6:135. 2007
  4. doi Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development
    David C Kaslow
    Merck Research Laboratories, Merck and Co Inc, North Wales, Pennsylvania 19454, USA
    Annu Rev Med 62:201-15. 2011
  5. ncbi Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter
    David C Kaslow
    Merck Research Laboratories, North Wales, Pennsylvania, USA
    Hum Vaccin 3:1-7. 2007
  6. ncbi Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses
    Rima Youil
    Merck and Company, West Point, PA 19486, USA
    Hum Gene Ther 14:1017-34. 2003
  7. ncbi Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens
    Fubao Wang
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Co, Inc West Point, PA 19486, USA
    Hum Gene Ther 14:25-36. 2003
  8. ncbi Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge
    Gretchen S Jimenez
    Vical Incorporated, San Diego, California 92121, USA
    Hum Vaccin 3:157-64. 2007
  9. ncbi A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases
    David C Kaslow
    Vical Incorporated, 10390 Pacific Center Court, San Diego, CA 92121 4340, USA
    Trans R Soc Trop Med Hyg 98:593-601. 2004
  10. ncbi Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge
    Adrian Vilalta
    Vical, San Diego, CA 92121, USA
    Hum Gene Ther 18:763-71. 2007

Collaborators

Detail Information

Publications16

  1. ncbi Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    John W Shiver
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Nature 415:331-5. 2002
    ..The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine...
  2. doi Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus
    Peggy A Lalor
    Vical, Inc, San Diego, California 92121, USA
    J Infect Dis 197:1643-52. 2008
    ..These experiments support the clinical testing of pDNA vaccine candidates that may ultimately increase global vaccine supply options during pandemics...
  3. pmc Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization
    George Jiang
    Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910 7500, USA
    Malar J 6:135. 2007
    ....
  4. doi Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development
    David C Kaslow
    Merck Research Laboratories, Merck and Co Inc, North Wales, Pennsylvania 19454, USA
    Annu Rev Med 62:201-15. 2011
    ..This review presents some emerging concepts that will likely shape efforts to develop active and passive immunization interventions in response to the reemergence of these bacterial pathogens...
  5. ncbi Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter
    David C Kaslow
    Merck Research Laboratories, North Wales, Pennsylvania, USA
    Hum Vaccin 3:1-7. 2007
    ..Both incubation period and broadly protective, relative immunogenicity appear to have accounted for much of the past successes in vaccine development, and may be useful in predicting where near term successes are most apt to occur...
  6. ncbi Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses
    Rima Youil
    Merck and Company, West Point, PA 19486, USA
    Hum Gene Ther 14:1017-34. 2003
    ..This increased robustness will be critical when adapting first-generation recombinant adenovectors to commercial production...
  7. ncbi Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens
    Fubao Wang
    Department of Virus and Cell Biology, Merck Research Laboratories, Merck and Co, Inc West Point, PA 19486, USA
    Hum Gene Ther 14:25-36. 2003
    ..This assay may be used for clinical trials using adenovirus vectors as vehicles for vaccines...
  8. ncbi Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge
    Gretchen S Jimenez
    Vical Incorporated, San Diego, California 92121, USA
    Hum Vaccin 3:157-64. 2007
    ..Vaxfectin adjuvanticity was confirmed with a low dose of HA pDNA. These promising proof-of-concept data support the clinical development of Vaxfectin-formulated pDNA encoding NP + M2 consensus proteins...
  9. ncbi A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases
    David C Kaslow
    Vical Incorporated, 10390 Pacific Center Court, San Diego, CA 92121 4340, USA
    Trans R Soc Trop Med Hyg 98:593-601. 2004
    ..A success against any one of the persistent intracellular pathogens would be sufficient proof that gene-based vaccines represent a disruptive technology against which future vaccine technologies will be measured...
  10. ncbi Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge
    Adrian Vilalta
    Vical, San Diego, CA 92121, USA
    Hum Gene Ther 18:763-71. 2007
    ..Vaccination with heterotypic H1 HA-LEC DNA provided no protection against viral challenge...
  11. ncbi Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines
    Vicky L Leamy
    Vical Incorporated, San Diego, California 92121, USA
    Hum Vaccin 2:113-8. 2006
    ..22 x 10(3) PCN/microg of total DNA for the low-dose volume murine model and 2.81 x 10(3)/microg DNA for the rabbit model. Interanimal variability in persistence was not impacted by dose volume...
  12. ncbi Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines
    Martha Sedegah
    Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910 7500, USA
    Vaccine 24:1921-7. 2006
    ..Clinical trials of pDNA vaccines have often used low pDNA doses based on a per kilogram weight basis. Formulation of pDNA vaccines in Vaxfectin may improve their potency in human clinical trials...
  13. ncbi II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential
    Adrian Vilalta
    Vical Incorporated, San Diego, CA 92121, USA
    Hum Gene Ther 16:1151-6. 2005
    ....
  14. ncbi I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration
    Adrian Vilalta
    Vical Incorporated, San Diego, CA 92121, USA
    Hum Gene Ther 16:1143-50. 2005
    ..Therefore the risk of genomic integration of hCMV pDNA formulated with poloxamer was considered negligible...
  15. ncbi A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulati
    Sanjai Kumar
    Malaria Program, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Immunol Lett 81:13-24. 2002
    ..The GM-CSF plasmid or protein appears to be less potent as an adjuvant in rhesus monkeys than each is in mice, and more work is needed to determine if GM-CSF can be a useful adjuvant in DNA vaccination of primates...
  16. pmc A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum
    Anthony W Stowers
    Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Rockville, MD 20852, USA
    Proc Natl Acad Sci U S A 99:339-44. 2002
    ..This study demonstrates the potential for producing efficacious malarial vaccines in transgenic animals...